YouTube Facebook LinkedIn Google+ Twitter Xingrss  

Champions LS eqt Agilent


March 7, 2002

Agilent Technologies Inc.
Chris van Ingen
Senior Vice President, General Manager, Chemical Analysis Group

Watch for Coming Nanopore Technology

What is the history of your organization’s involvement in life sciences?
van Ingen
: Our company has been involved in providing instrument solutions to the life sciences in some form or another for at least 30 years. With the emergence of genomics and proteomics, the focus has become far more intense as these markets have grown in importance. For instrument companies like Agilent it has become an imperative to transition towards becoming a major solutions supplier to this industry to ensure long-term business growth.

What is your vision for the development of the life sciences market?
van Ingen
: Personally I am very bullish about this business and can see a long-term period of profitable growth both in revenues and in market share in the markets in which we operate. Gene expression, proteomics, and drug discovery and development are the three key immediate markets that Agilent serves.

What organizational assets have you developed to serve this community?
van Ingen
: I would have to say the alignment of our organization into businesses that focus on these specific market segments. Our bioresearch solutions business is very clearly focused on the gene expression market, with its associated drug and disease discovery segments, and our pharmaceutical solutions business is focused on bringing solutions to proteomics and pharmaceutical quality control and the drug discovery development segments of the pharmaceutical value chain. We also serve the bioagricultural market.

What products and services does your company provide to the life sciences market?
van Ingen
: The primary solutions that our company offers hinge on four major platforms: cDNA microarrays, microfluidics, liquid chromatography, and mass-spectrometry, along with the associated supplies, services, and bioinformatics. Each platform has a myriad of specialized solutions that have been developed to meet the specified needs of our customers.

What new products and services do you have in development?
van Ingen
: It is not Agilent policy to discuss products that may or may not be in development. I can say however we are investigating two important new technologies that we recently announced. The first is nanopore technology, which we are investigating with Harvard, and the second is new DNA synthesis technology, which we are investigating with the University of Colorado and with the Department of Defense.
www.agilent.com/chem

Return to main index page.

View Next Related Story
Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1


For reprints and/or copyright permission, please contact  Terry Manning, 781.972.1349 , tmanning@healthtech.com.